Figure S1. Optimisation of bortezomib concentration by
comparison with 10 µM MG132. (A) Schematic of the experimental
workflow. HFFF-TERT cells were infected with Merlin strain HCMV (MOI 5)
or mock infected. After 12h of infection, cells were treated with 10 µM
MG132 or 50 nM, 150 nM or 500 nM of bortezomib for a further 12 h and
harvested for analysis at 24 hpi. Whole cell lysates were digested into
peptides, which were labelled with TMT reagents followed by MS3 mass
spectrometry. (B) Comparison of 10 µM MG132 with 50 nM, 150 nM or 500 nM
bortezomib (bort).